ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Paving the way for optimal disease control in moderate-to-severe type 2 asthma"
Episode Synopsis
touchPANEL DISCUSSION for touchIMMUNOLOGY
Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions.
The experts
Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA
Dr Roland Buhl - Mainz University Hospital, Mainz, Germany
Dr Flavia Hoyte - National Jewish Health and University of Colorado, Denver, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME.
For further information visit our website: https://touchimmunologyime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/
Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions.
The experts
Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA
Dr Roland Buhl - Mainz University Hospital, Mainz, Germany
Dr Flavia Hoyte - National Jewish Health and University of Colorado, Denver, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME.
For further information visit our website: https://touchimmunologyime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/
In God we trust